Mirae Asset Global Investments
TCRX icon

Mirae Asset Global Investments’s TScan Therapeutics TCRX Stock Holding History

Mirae Asset Global Investments’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,029
Closed -$3.69K – 1741
2025
Q3 		$3.69K Buy
2,029
+8
+0.4% +$14 ﹤0.01% 1621
2025
Q2 		$2.93K Buy
2,021
+465
+30% +$672 ﹤0.01% 1555
2025
Q1 		$2.1K Sell
1,556
-80
-5% -$173 ﹤0.01% 1537
2024
Q4 		$5.01K Buy
+1,636
New +$7.42K ﹤0.01% 1560

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $508M AUM 163.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return

Mirae Asset Global Investments's TCRX Position: Q4 2025 in Review

Mirae Asset Global Investments sold out of TScan Therapeutics (TCRX) in Q4 2025, closing a stake of 2,029 shares — an estimated $3.69K sold.

Mirae Asset Global Investments first reported a position in TCRX in Q4 2024 and held it in 4 quarters. The position peaked at $5.01K in Q4 2024. 61 funds tracked by Wall St. Rank hold TCRX as of Q4 2025.

  • Mirae Asset Global Investments reported no remaining TScan Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Mirae Asset Global Investments sold 2,029 TScan Therapeutics shares in Q4 2025, an estimated $3.69K.
  • Mirae Asset Global Investments first reported a position in TScan Therapeutics in Q4 2024 and held it in 4 quarters.
  • Mirae Asset Global Investments's TScan Therapeutics position peaked at $5.01K in Q4 2024.
  • 61 funds tracked by Wall St. Rank held TScan Therapeutics as of Q4 2025.

Based on Mirae Asset Global Investments's 13F filing for Q4 2025, filed 26 Jan 2026.